GSK aims to impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. GSK will be a company where outstanding people can thrive.

Our strategy
We will prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccine and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology including respiratory diseases.

Our culture
We’re focused on making GSK a place where everyone can be ambitious for patients, accountable for their impact and always do the right thing. Our Code outlines the commitments we ask everyone at GSK to put their name to with pride.

Our brand
We have updated our branding to reflect our new purpose and growth ambitions. It combines science, technology, and talent, while retaining key elements of our heritage.

Menveo is a quadrivalent meningococcal vaccine that can be administered from 2 months of age1. Invasive meningococcal disease progresses so rapidly that 8-15% of patients die within 24-48 hours of symptoms. The fatality rate is higher without proper treatment and serious sequelae may remain2.
 
After approval by the US FDA and European EMA in 20103,4, Menveo received approval in Korea in May 2012 from the Ministry of Food and Drug Safety for adolescents and adults aged 2 months to 55 years old. Currently5,6, Menveo is the only quadrivalent meningococcal vaccine available in Korea from infants over 2 months of age to age 551,7.
 
Menveo showed high immunogenicity and tolerability in infants, adolescents, and adults8,9,10,11,12. High immunogenicity and tolerability were recognized when Menveo was administered four times in 2-month-old infants1.